Abivax S.A. 正稳步推进其研发管线。该公司重申,其目标明确——计划于2026年底前,正式向监管机构提交Obefazimod的首项新药申请(NDA)。这项申请旨在寻求该药物用于治疗中重度活动性溃疡性结肠炎(UC)的上市许可。这一进展,标志着公司在关键临床项目上迈出了坚实的一步。
Abivax S.A. 正稳步推进其研发管线。该公司重申,其目标明确——计划于2026年底前,正式向监管机构提交Obefazimod的首项新药申请(NDA)。这项申请旨在寻求该药物用于治疗中重度活动性溃疡性结肠炎(UC)的上市许可。这一进展,标志着公司在关键临床项目上迈出了坚实的一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.